Ys Biopharma Co Stock Analysis

YS Stock   0.56  0.06  9.68%   
The main objective of YS Biopharma stock analysis is to determine its intrinsic value, which is an estimate of what YS Biopharma Co is worth, separate from its market price. There are two main types of YS Biopharma's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect YS Biopharma's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of YS Biopharma's stock to identify patterns and trends that may indicate its future price movements.
The YS Biopharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. YS Biopharma is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. YS Biopharma Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and YS Biopharma's ongoing operational relationships across important fundamental and technical indicators.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in YS Biopharma Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

YS Biopharma Stock Analysis Notes

About 14.0% of the company outstanding shares are owned by institutional investors. The company recorded a loss per share of 0.29. YS Biopharma had not issued any dividends in recent years.

YS Biopharma Quarterly Cost of Revenue

34.68 Million

YS Biopharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. YS Biopharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding YS Biopharma Co or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
YS Biopharma generated a negative expected return over the last 90 days
YS Biopharma has high historical volatility and very poor performance
YS Biopharma has some characteristics of a very speculative penny stock
YS Biopharma has a very high chance of going through financial distress in the upcoming years
The company generated the yearly revenue of 687.2 M. Annual Net Loss to common stockholders was (145.48 M) with gross profit of 0.
YS Biopharma generates negative cash flow from operations
Latest headline from news.google.com: Noble Capital Markets Initiates Coverage on YS Biopharma With ... - Marketscreener.com

YS Biopharma Upcoming and Recent Events

Earnings reports are used by YS Biopharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to YS Biopharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
27th of November 2023
Upcoming Quarterly Report
30th of September 2023
Next Fiscal Quarter End
30th of June 2023
Last Quarter Report
31st of March 2023
Last Financial Announcement

YS Biopharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. YS Biopharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that YS Biopharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial YS Biopharma specific information freely available to individual and institutional investors to make a timely investment decision.

YS Biopharma Thematic Classifications

In addition to having YS Biopharma stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products Idea
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

YS Biopharma Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as YS Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading YS Biopharma Co backward and forwards among themselves. YS Biopharma's institutional investor refers to the entity that pools money to purchase YS Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Last TransactionTypeSharesValue
Glazer Capital Llc2022-12-31Common Shares1.7 M17.4 M
Aristeia Capital Llc2022-12-31Common Shares1.6 M16.1 M
Marshall Wace Llp2022-12-31Common Shares593.9 KM
Woodline Partners Lp2022-12-31Common Shares367.6 K3.7 M
Orbimed Advisors Llc2023-09-30Common Shares4.5 M3.6 M
Bank Of America Corp2022-12-31Common Shares340 K3.4 M
Goldman Sachs Group Inc2022-12-31Common Shares301.9 KM
Centiva Capital Lp2022-12-31Common Shares228.4 K2.3 M
Fil Ltd2023-09-30Common Shares2.7 M2.2 M
Cowen Investment Management Llc2022-12-31Common Shares200 KM
Weiss Asset Management Lp2022-12-31Common Shares200 KM
Note, although YS Biopharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

YS Biopharma Market Capitalization

The company currently falls under 'Micro-Cap' category with a market capitalization of 44.67 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate YS Biopharma's market, we take the total number of its shares issued and multiply it by YS Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

YS Biopharma Profitablity

YS Biopharma's profitability indicators refer to fundamental financial ratios that showcase YS Biopharma's ability to generate income relative to its revenue or operating costs. If, let's say, YS Biopharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, YS Biopharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of YS Biopharma's profitability requires more research than a typical breakdown of YS Biopharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Net Profit Margin (PM) of (0.45) %, which may indicate that it does not properly execute on its own pricing strategies. This is way below average. Likewise, it shows Net Operating Margin (NOM) of (0.4) %, which signifies that for every 100 dollars of sales, it has a net operating loss of $0.4.
Last ReportedProjected for 2023
Return on Average Assets(0.27)(0.29)
Return on Average Equity(28.59)(29.34)
Return on Invested Capital(0.24)(0.26)
Return on Sales(0.37)(0.39)

Management Efficiency

Return on Average Assets is likely to drop to -0.29 in 2023. Return on Average Equity is likely to drop to -29.34 in 2023. At this time, YS Biopharma's Total Assets are comparatively stable as compared to the past year. Assets Non Current is likely to gain to about 706.2 M in 2023, whereas Goodwill and Intangible Assets are likely to drop slightly above 75.1 M in 2023. YS Biopharma's management efficiency ratios could be used to measure how well YS Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.
Last ReportedProjected for 2023
Book Value per Share 7.83  8.45 
Enterprise Value over EBIT(2.00)(2.16)
Enterprise Value over EBITDA(1.82)(1.96)
Price to Book Value 0.20  0.22 
Tangible Assets Book Value per Share 17.64  20.32 
Enterprise Value383.4 M384.9 M
Tangible Asset Value1.6 B1.7 B
The analysis of YS Biopharma's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze YS Biopharma's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of YS Biopharma Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.

Technical Drivers

As of the 30th of November, YS Biopharma owns the information ratio of (0.17), and Market Risk Adjusted Performance of (4.78). Concerning fundamental indicators, the technical analysis model lets you check potential technical drivers of YS Biopharma, as well as the relationship between them. Strictly speaking, you can use this information to find out if the company will indeed mirror its model of historical prices and volume patterns, or the prices will eventually revert. We are able to interpolate and collect thirteen technical drivers for YS Biopharma, which can be compared to its peers in the sector. Please check out YS Biopharma standard deviation, as well as the relationship between the treynor ratio and potential upside to decide if YS Biopharma Co is priced fairly, providing market reflects its prevailing price of 0.56 per share. As YS Biopharma is a penny stock we also advise to confirm its jensen alpha numbers.

YS Biopharma Price Movement Analysis

Execute Study
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. YS Biopharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for YS Biopharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

YS Biopharma Predictive Daily Indicators

YS Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of YS Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

YS Biopharma Forecast Models

YS Biopharma's time-series forecasting models are one of many YS Biopharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary YS Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About YS Biopharma Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how YS Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling YS Biopharma shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as YS Biopharma. By using and applying YS Biopharma Stock analysis, traders can create a robust methodology for identifying YS Biopharma entry and exit points for their positions.
Last ReportedProjected for 2023
EBITDA Margin(0.31)(0.33)
Gross Margin 0.78  0.86 
Profit Margin(0.61)(0.66)

Current YS Biopharma Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. YS Biopharma analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. YS Biopharma analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
5.25Strong Buy1Odds
YS Biopharma Co current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most YS Biopharma analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand YS Biopharma stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of YS Biopharma, talking to its executives and customers, or listening to YS Biopharma conference calls.
YS Biopharma Analyst Advice Details

YS Biopharma Stock Analysis Indicators

YS Biopharma Co stock analysis indicators help investors evaluate how YS Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading YS Biopharma shares will generate the highest return on investment. By understating and applying YS Biopharma stock analysis, traders can identify YS Biopharma position entry and exit signals to maximize returns.
Begin Period Cash Flow271.1 M
Long Term Debt293.8 M
Common Stock Shares Outstanding93.1 M
Total Stockholder Equity728.5 M
Tax Provision1.1 M
Property Plant And Equipment Net582.9 M
Cash And Short Term Investments370.1 M
Cash370.1 M
Accounts Payable80.4 M
Net Debt128.5 M
50 Day M A0.8772
Total Current Liabilities658.8 M
Other Operating Expenses800.5 M
Non Current Assets Total683.8 M
Non Currrent Assets Other20.9 M
Stock Based Compensation3.5 M
When determining whether YS Biopharma is a strong investment it is important to analyze YS Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact YS Biopharma's future performance. For an informed investment choice regarding YS Biopharma Stock, refer to the following important reports:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in YS Biopharma Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Complementary Tools for YS Biopharma Stock analysis

When running YS Biopharma's price analysis, check to measure YS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy YS Biopharma is operating at the current time. Most of YS Biopharma's value examination focuses on studying past and present price action to predict the probability of YS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move YS Biopharma's price. Additionally, you may evaluate how the addition of YS Biopharma to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Bonds Directory
Find actively traded corporate debentures issued by US companies
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Is YS Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of YS Biopharma. If investors know YS Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about YS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
Return On Equity
The market value of YS Biopharma is measured differently than its book value, which is the value of YS Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of YS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is YS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because YS Biopharma's market value can be influenced by many factors that don't directly affect YS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between YS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if YS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, YS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.